Publications by authors named "Catherine Blaker"
Background: Distinguishing benign from malignant pancreaticobiliary disease is challenging because of the absence of reliable biomarkers. Circulating extracellular vesicles (EVs) have emerged as functional mediators between cells. Their cargos, including microRNAs (miRNAs), are increasingly acknowledged as an important source of potential biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- The Phase III CAPItello-291 trial showed that combining capivasertib (an AKT inhibitor) and fulvestrant (a SERD) improved progression-free survival for HR+ breast cancer patients after aromatase inhibitors, but prior treatment with CDK4/6 inhibitors may lessen the effectiveness of future endocrine therapies.
- Researchers examined how CDK4/6 inhibitors affect the function of estrogen receptor-positive (ER+) breast cancer cells and their responses to fulvestrant and capivasertib, finding varied gene expression and signaling alterations in resistant cell lines.
- Despite reduced efficacy and changes in cellular signaling in both RB+ and RB- resistant models, the combination therapy was still effective in reducing cell cycle activity
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons (MNs). There are no effective treatments and patients usually die within 2-5 years of diagnosis. Emerging commonalities between familial and sporadic cases of this complex multifactorial disorder include disruption to RNA processing and cytoplasmic inclusion bodies containing TDP-43 and/or FUS protein aggregates.
View Article and Find Full Text PDF